SecBot SecBot
Biotech Drug Report Generated Oct 28, 2026

Fanapt

VNDA·Vanda Pharmaceuticals Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available since 2009 (schizophrenia) and 2024 (bipolar I disorder).
Why 4/10
Fanapt is already FDA-approved and commercially marketed with no pending regulatory decision or pivotal readout. The next hard catalyst for the stock is the December 12, 2026 PDUFA for imsidolimab (a different drug), not for Fanapt. Per the rubric, an approved drug with no pending binary scores 3-5, and Fanapt is Vanda's largest product but the company also has other approved products and pipeline, so the score is 4.
Actionable Insight NEUTRAL

Fanapt has no hard binary catalyst in the next 12 months. Watch the Q3 2026 earnings call today (October 28) for the latest Fanapt prescription trends, as well as the December 12, 2026 PDUFA for imsidolimab (a different Vanda asset). The key long-term question is how quickly the next-gen asset BYSANTI (milsaperidone, approved February 2026) cannibalizes or replaces Fanapt revenue as generic iloperidone pressure builds.

Price Chart

Loading chart...

Executive Summary

Fanapt (iloperidone) is an FDA-approved atypical antipsychotic marketed by Vanda Pharmaceuticals (Nasdaq: VNDA). Originally approved for schizophrenia in 2009, Fanapt received a label expansion in April 2024 for acute manic or mixed episodes associated with bipolar I disorder. It generated $117.3 million in net sales in 2025 (up 24% year-over-year), representing 54% of Vanda's total revenue. Prescription growth remains strong, with total prescriptions up 31% YoY in Q2 2026. However, the drug faces generic competition (at least 3 approved generics), and Vanda has already developed a next-generation follow-on called BYSANTI (milsaperidone), an active metabolite of Fanapt approved as a new chemical entity in February 2026. With no pending regulatory catalyst specific to Fanapt, the stock's next major binary event is the December 12, 2026 PDUFA for imsidolimab, an unrelated Vanda pipeline asset.

How It Works

Fanapt is an atypical antipsychotic, a class of drugs that alters the activity of certain natural chemicals (dopamine and serotonin) in the brain. It is thought to work by blocking dopamine type 2 (D2) and serotonin type 2 (5-HT2) receptors, which helps reduce hallucinations, delusions, and other symptoms of schizophrenia, as well as stabilize mood in bipolar I disorder.

Trial Status

Fanapt is fully approved and marketed in the U.S. for schizophrenia (since 2009) and acute manic/mixed episodes of bipolar I disorder (since April 2024). It is an established commercial product with growing prescription trends.

The Two-Sided Case

▲ Bull Case4
Fanapt prescription growth is accelerating: total prescriptions rose 31% YoY and new-to-brand prescriptions rose 32% YoY in Q2 2026, driven by the newer bipolar I disorder label expansion.
Fanapt generated $117.3M in net sales in 2025 (up 24% YoY) and represents 54% of Vanda's total revenue, making it the company's largest and fastest-growing commercial product.
Vanda developed BYSANTI (milsaperidone), an active metabolite of Fanapt approved as a new chemical entity in February 2026 with patent protection extending to the 2040s, providing a follow-on lifecycle strategy.
Analyst consensus is strongly bullish: 9 of 11 analysts rate Vanda a Buy or Strong Buy, with a mean price target of $11.50 (198% upside from the current ~$4.00), and several institutional investors added or doubled positions in Q2 2026.
▼ Bear Case4
Generic iloperidone is already available from at least 3 manufacturers, which limits pricing power and long-term revenue growth potential for Fanapt.
The FDA approval of BYSANTI (milsaperidone), Fanapt's own active metabolite, introduces a potential cannibalization risk if patients and prescribers switch to the newer chemical entity.
Vanda's total revenue is under pressure beyond Fanapt: HETLIOZ sales declined 66% YoY in Q2 2026 due to generic competition, and the company is burning cash according to some analysts.
Short interest is elevated at ~13.7% of estimated shares outstanding (as of Oct 15, 2026), reflecting bearish positioning by some investors.

Upcoming Catalysts

  • No upcoming PDUFA or pivotal readout specific to Fanapt. The Q3 2026 earnings call (today, October 28, 2026) will provide updated Fanapt prescription and revenue data. The next company-level catalyst is the December 12, 2026 PDUFA for imsidolimab (imsidolimab) in generalized pustular psorasis.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Vanda Pharmaceuticals Inc. 8-K VNDA ·Originating report

Sources · 3

Hover a chip for the title
1 vandapharma.com2 fanapt.com3 prnewswire.com